Haemodynamic (HD) evaluation of LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH)
B. Egenlauf (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), S. Patel (Morrisville, United States), A. Galloway (Morrisville, United States), E. Grünig (Heidelberg, Germany)
Source: International Congress 2022 – Treatment of pulmonary arterial hypertension
Session: Treatment of pulmonary arterial hypertension
Session type: Thematic Poster
Number: 2673
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Egenlauf (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), S. Patel (Morrisville, United States), A. Galloway (Morrisville, United States), E. Grünig (Heidelberg, Germany). Haemodynamic (HD) evaluation of LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). 2673
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|